Changing of Val47 to Asp47 or to Lys47 enhances the immunomodulatory activity of the human Interleukin-l peptide 47–55
The 47–55 domain of the maturehumanInterleukin-was predicted to be exposed by our computational analysis and confirmed to be so by comparing with X-ray crystallographic as well as nuclear magnetic resonance (NMR) spectroscopic data. Four peptides representing fully or part of this domain with sequences 47–55, 41–61, 45–61 and 50–66 were synthesized and tested for their ability to modulate in vivo, the humoral immune response of Balb/c mice to Shigella dysenteriae 116 kDa antigen(s). The smallest immunomodulatory peptide amongst them was found to be the nonapeptide 47–55. To ascertain the structure-function relationships of this 47–55 peptide, various mutant peptides were synthesized and tested for IL-1β 2 like activity in vivo. Change of Val47 to Asp47 or to Lys47 enhanced its immunomodulatory activity significantly while the change of Gly49 to Asp49 or Glu50 to Ile50 or Asp54 to Ile54 had no such effect. The peptides 47–55 and its mutants were first tested for their ability to elicit inflammatory response like PGE2 synthesis by a sensitive radioimmunoassay. The peptides which did not have any inflammatory activity were then tested for their ability to stimulate antigen primed T-cells in vitro in the presence of sub-optimal concentration of the antigen.
KeywordsInterleukin-l peptide 47–55 immunomodulation Shigella dysenteriae 116 kDa antigen exposed domain mutant peptides
Unable to display preview. Download preview PDF.
- Atherton E and Sheppard R C 1989Solid Phase Peptide Synthesis: A practical approach (Oxford: IRL Press)Google Scholar
- Chou P Y and Fasman G D 1979 Prediction of beta turns;Biophys. J. 26 367–373Google Scholar
- Kaye J, Gillis S, Mizel S B, Shevac E M, Malek T R, Dinarello A. A, Lachman L B and Janeway A. A Jr 1984 Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: Interleukin-1 is required for expression of receptor for Interleukin-2;J. Immunol. 133 1339–1345PubMedGoogle Scholar